Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

81.62 +11.36 (+16.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance. 
Via Benzinga
Nasdaq 100 Leads Wall Street Rally As China Signals Openness To Fentanyl Talks, Easing Trade Tensions
U.S. stocks rose on hopes of China's willingness to negotiate a trade deal regarding fentanyl production. Tech stocks led the rally. 
Via Benzinga
Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What's Driving Markets Friday?
U.S. stocks advanced across the board by midday Friday, with the S&P 500 eyeing its ninth consecutive day of gains—poised for the longest winning streak since May 2024. 
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
A Look Into DexCom Inc's Price Over Earnings
Via Benzinga
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Via Benzinga
2 Growth Stocks to Buy and Hold for a Decade
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
DexCom (NASDAQ:DXCM) Exceeds Q1 Expectations
Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be... 
Via StockStory
Exposures Product Safety
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
From DexCom, Inc.
Via Business Wire
Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday?
Wall Street pushed higher in midday trading, with the S&P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully... 
Via Benzinga
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
DexCom (DXCM) Q1 Earnings: What To Expect
Medical device company DexCom (NASDAQ:DXCM) will be reporting results tomorrow after market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U
From DexCom, Inc.
Via Business Wire
2 Cash-Producing Stocks That Stand Out and 1 to Keep Off Your Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Exposures Product Safety
3 New ETFs Finding Early Traction With Investors
Markets have tumbled in 2025, but three funds launched this year have the potential to outshine even longer-established ETFs. 
Via MarketBeat
Topics ETFs
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
From Johnson Fistel, PLLP
Via Business Wire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Tariffs, Trump, and Turmoil
Via The Motley Fool
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
What Does the Market Think About DexCom?
Via Benzinga
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
Dexcom G7 15-Day CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features. 
Via Benzinga
Exposures Product Safety
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Exposures Artificial Intelligence Economy Political
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Dexcom Surges After FDA Clears Its Next-Generation Diabetes Device
Dexcom stock surged Thursday after the FDA cleared its newest diabetes device for an extended 15-day wear time. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Product Safety Tariff
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
From DexCom, Inc.
Via Business Wire
What 6 Analyst Ratings Have To Say About DexCom
Via Benzinga
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.